Could RICO Finally Hold Big Pharma Accountable for Hidden Drug Risks?

In a groundbreaking development for pharmaceutical accountability, Wisner Baum LLP has pushed a novel use of the Racketeer Influenced and Corrupt Organizations Act (RICO) into the national spotlight. The firm has secured appellate affirmation of class certification in a first-of-its-kind civil RICO suit against major drugmakers Takeda and Eli Lilly. At stake are alleged years of concealed cancer risks tied to the diabetes drug Actos — and potentially billions of dollars in treble damages for those harmed by pharmaceutical fraud. This move could forge a new frontline for plaintiffs and attorneys seeking systemic corporate transparency and justice.

What Is the Actos RICO Case and Why It Matters

The case — Painters & Allied Trades District Council 82 Health Care Fund v. Takeda Pharmaceutical Co. Ltd. — alleges Takeda and Eli Lilly systematically hid data showing Actos (pioglitazone) significantly elevated bladder cancer risk. Plaintiffs assert internal company records showed awareness of the risk long before disclosure, and that this deception affected pricing, prescriptions, and insurance payouts nationwide. The Ninth Circuit Court of Appeals recently upheld a district court’s certification of a national RICO class action for third-party payers — a milestone rarely seen against pharmaceutical manufacturers. 

Class certification under RICO is significant because it allows treble damages (three-times actual losses) and penalties designed to punish and deter fraudulent conduct. Traditionally, RICO has been associated with mob prosecutions and civil claims against organized crime — not pharmaceutical misrepresentation. Plaintiffs’ counsel argue this shift empowers courts to address alleged corporate deception at a structural level rather than piecemeal in individual suits. 

Key Points

• The suit alleges that Takeda and Eli Lilly concealed Actos bladder cancer risks for over a decade. 

• The Ninth Circuit affirmed the unique national RICO class certification. 

• RICO’s treble-damages framework vastly increases potential recovery.

• The case could catalyze broader legal strategies against systemic pharmaceutical misconduct. 

Why Plaintiffs Are Turning to RICO in Pharmaceutical Cases

Plaintiff attorneys nationwide have long struggled with the economic and procedural hurdles of confronting well-funded drugmakers. Standard negligence and product liability claims often drag on for years and yield modest individual damages relative to the costs of litigation. By contrast, RICO opens the door to statutory damage multipliers and broader discovery into patterns of corporate conduct. 

Consumer advocates and some legal analysts view this as a paradigm shift — one that could allow courts to examine whether decades of marketing, nondisclosure, and suppression of safety data rises to coordinated enterprise fraud. Even if plaintiffs ultimately face challenges at trial, the ability to pursue discovery and hold corporations publicly accountable is a major strategic win. 

RICO Advantages

• Treble damages offer significant leverage against deep-pocketed defendants. 

• Class actions centralize claims for efficiency and consistency. 

• RICO’s broad definitions can capture alleged coordinated concealment efforts. 

• Appeals affirmation signals judicial willingness to apply RICO beyond traditional contexts. 

Potential Impacts on the Pharmaceutical Industry

If this RICO strategy succeeds at trial, it could have ripple effects across the pharmaceutical landscape. Regulators, lawmakers, and plaintiffs’ lawyers alike are watching closely. The threat of tripled financial liability and rigorous discovery into internal corporate practices may push drugmakers to disclose risk data more proactively. Some industry observers note heightened regulatory scrutiny throughout 2025, including FDA enforcement actions against deceptive drug advertising, suggesting a broader climate of accountability. 

For class-action counsel and injured parties, this may signal that courts are prepared to look beyond conventional negligence frameworks toward systemic remedies — especially where alleged fraud affects large populations, insurers, and public trust. 

Industry Consequences

• New regulatory scrutiny may intersect with litigation pressure. 

• Drugmakers may face increased exposure for nondisclosure and deceptive practices. 

• Plaintiffs may pursue similar RICO strategies in other healthcare contexts. 

• Insurance payers and employers could have significant recoveries if suit succeeds. 

What Plaintiffs and Attorneys Should Watch Next

The Actos RICO class will now move toward merits discovery and eventual trial — a process that could unfold over several years. Plaintiffs’ counsel will look to build evidence showing that Takeda and Eli Lilly not only failed to disclose safety data, but did so in a way that amounts to a pattern of racketeering activity under federal law. Defense counsel will likely challenge both the factual basis and the legal applicability of RICO in pharmaceutical contexts.

For injured individuals and third-party payers, this litigation underscored the importance of preserving documentation, understanding regulatory history, and consulting experienced counsel who can navigate complex class actions.

Strategic Takeaways

• RICO application in pharma is rare but potentially powerful. 

• Early appellate success improves plaintiffs’ bargaining position. 

• Broader discovery could illuminate hidden corporate practices. 

• Merits phase will test factual allegations and legal theories. 

Conclusion

The Wisner Baum RICO action against Takeda and Eli Lilly marks a watershed in pharmaceutical litigation strategy. By harnessing a statute designed to combat organized fraud, plaintiffs are seeking a transformative form of accountability against alleged concealment of cancer risks tied to a blockbuster drug. While the path to verdict remains long and arduous, the implications for plaintiffs, attorneys, industry practices, and future healthcare litigation are profound. This case may well become a touchstone for how courts and litigators address systemic corporate deception in the 21st century.